Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 30.29M | 28.05M | 22.52M | 17.13M | 23.23M | 16.08M |
Gross Profit | 5.73M | -109.00K | -5.49M | -8.54M | -7.74M | -8.07M |
EBITDA | -43.92M | -46.56M | -53.46M | -60.38M | -45.80M | -32.00M |
Net Income | -44.11M | -46.89M | -52.47M | -60.81M | -73.52M | -37.08M |
Balance Sheet | ||||||
Total Assets | 75.59M | 98.17M | 143.45M | 190.65M | 241.17M | 70.00M |
Cash, Cash Equivalents and Short-Term Investments | 31.25M | 50.73M | 92.05M | 108.65M | 193.50M | 45.08M |
Total Debt | 5.58M | 6.17M | 7.35M | 7.97M | 400.00K | 24.81M |
Total Liabilities | 21.04M | 22.82M | 25.46M | 26.48M | 20.19M | 45.18M |
Stockholders Equity | 54.55M | 75.35M | 117.99M | 164.17M | 220.98M | 24.82M |
Cash Flow | ||||||
Free Cash Flow | -38.28M | -45.52M | -46.93M | -65.29M | -58.18M | -31.69M |
Operating Cash Flow | -37.27M | -44.15M | -45.08M | -58.55M | -54.96M | -31.00M |
Investing Cash Flow | 18.35M | 36.66M | 42.15M | -93.47M | -13.29M | -15.67M |
Financing Cash Flow | 136.00K | 203.00K | 149.00K | 693.00K | 216.75M | 64.23M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
67 Neutral | $96.92M | 12.52 | 4.83% | ― | 1.43% | -20.12% | |
63 Neutral | $289.05M | -3.74 | -12.39% | ― | 14.65% | -86.36% | |
58 Neutral | $50.96M | -58.94 | 11.91% | ― | 3.30% | -112.70% | |
52 Neutral | $83.58M | -17.96 | -9.44% | ― | 15.16% | -39.18% | |
49 Neutral | $145.89M | ― | -59.15% | ― | 22.57% | 14.11% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
On August 8, 2025, Rapid Micro Biosystems entered into a Loan and Security Agreement with Trinity Capital Inc., securing a $45 million term loan facility to bolster its financial position and support long-term growth. The company reported a 10% increase in total revenue for the second quarter of 2025 compared to the previous year, driven by strong performance in service and product revenue, and reaffirmed its full-year revenue guidance of at least $32 million.
On June 17, 2025, Robert Spignesi, CEO of Rapid Micro Biosystems, announced his diagnosis with a treatable form of Lymphoma. Despite the diagnosis and ongoing treatment, Spignesi plans to continue leading the company with limited in-person presence, expressing confidence in the company’s ability to maintain its performance and thanking the team for their support.